Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: When is immediate treatment optimal?

Clinical Infectious Diseases

Volumn 55, Issue 10, 2012, Pages 1392-1399

  Negoescu, Diana M ^a   Owens, Douglas K ^b,c   Brandeau, Margaret L ^a   Bendavid, Eran ^c,d  

^a Stanford University   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c Center for Health Policy   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

AGE; ANTIVIRAL THERAPY; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MATHEMATICAL MODEL; MORTALITY; PATIENT PREFERENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SEX; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PATIENT PREFERENCE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84868024309     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis731     Document Type: Article

References (37)

1. Ho D. Time to hit HIV, early and hard. N Engl J Med 1995; 333:450-1.
2. Cozzi Lepri A, Phillips N, d'Arminio Monforte A, et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS 2001; 15:983-90.
3. Harrington M, Carpenter CC. Hit HIV-1 hard, but only when necessary. Lancet 2000; 355:2147-52.
4. Cain LE, Logan R, Robins JM, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med 2011; 154:509-15.
5. Shepherd BE, Jenkins C, Rebeiro PF, et al. Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Epidemiology 2010; 21:698-705.
6. Sterne JC, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-63.
7. Wang C, Vlahov D, Galai N, et al. Mortality in HIV-seropositive versus-seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004; 190:1046-54.
8. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.
9. Babiker AG, Emery S, Fatkenheuer G, et al. Considerations in the rationale, design and methods of the Strategic Timing of Anti-Retroviral Treatment (START) study. Clin Trials 2012. Available at: http://ctj.sagepub.com/ content/early/recent.
10. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-35.
11. Friis-Møller N, Sabin C, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
12. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:318-30.
13. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, Shlipak MG. Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS 2011; 25:1289-98.
14. El-Sadr W, Lundgren JD, Neaton J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-96.
15. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-26.
16. Writing Committee for the CASCADE Collaboration. Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med 2011; 171:1560-9.
17. Achhra AC, Amin J, Law MG, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIVinfected patients. AIDS 2010; 24:1877-86.
18. Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51:435-47.
19. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262-70.
20. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010; 55:615-9.
21. Schackman BR, Freedberg KA, Weinstein MC, et al. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med 2002; 162:2478-86.
22. Braithwaite RS, Roberts MS, Chang CCH, et al. Influence of alternative thresholds for initiating HIV treatment on qualityadjusted life expectancy: a decision model. Ann Intern Med 2008; 148:178-85.
23. Piroth L, Fournel I, Mahy S, et al. A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients. Epidemiol Infect 2011; 139:1835-44.
24. Shechter SM, Bailey MD, Schaefer AJ, Roberts MS. The optimal time to initiate HIV therapy under ordered health states. Oper Res 2008; 56:20-33.
25. Palella FJ, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med 2003; 138:620-6.
26. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 28 July 2011.
27. Bertsekas DP. Dynamic Programming and Optimal Control. 3rd ed. Belmont, MA: Athena Scientific, 2005.
28. Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
29. Arias E. United States life tables, 2006. Natl Vital Stat Rep 2010; 58:1.
30. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B. Deaths: final data for 2006. Natl Vital Stat Rep 2009; 57:1.
31. D:A:D Study Group, Sabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417-26.
32. Law M, Friis-Møller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med 2006; 7:218-30.
33. Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-29.
34. Phillips AN, Gazzard B, Gilson R, et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS 2007; 21:1717-21.
35. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145:397-406.
36. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS One 2011; 6:e17502.
37. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-95.